Centivax, a San Francisco, CA-based immunity firm offering a proprietary computational immune-engineering platform, raised $45M in Sequence A funding.
The spherical was led by Steve Jurvetson of Future Ventures, an early backer of Tesla, SpaceX, Prellis Biologics, Cambrian Bio, and others which in combination signify $1.4 Trillion of worth creation. Different traders included NFX, BOLD Capital Companions, Base4 Capital, Kendall Capital Companions, Amplify Companions.
The corporate intends to make use of the funds to speed up its first scientific candidate, a common flu vaccine at the moment in CMC improvement, by a Section I scientific trial slated to start inside eight months.
Led by CEO and founder Dr. Jacob Glanville, Centivax is an immunity firm, deploying a proprietary computational immune-engineering platform to create vaccines and therapies that ship common safety in opposition to whole courses of numerous targets. The lead scientific candidate for influenza—featured in The New Yorker, the Netflix docuseries Pandemic: Find out how to Forestall an Outbreak, and different shops—addresses a higher than $7 Billion international flu market, with follow-on applications spanning a rising pipeline for RSV/hMPV, herpesviruses, HIV, malaria, oncology, and a common antivenom.
The group additionally consists of Chief Innovation Officer Dr. Gusti Zeiner, Chief Operations Officer and co-founder David Tsao, and Chief Expertise Officer and co-founder Dr. Nicholas Bayless.
Along with enterprise backing, Centivax has secured $24M up to now in aggressive, non-dilutive awards, starting with a $2M “Grand Problem: Finish the Pandemic Menace” grant from the Invoice & Melinda Gates Basis and adopted by awards from CEPI, the Nationwide Institutes of Well being, the Army Infectious Illnesses Analysis Program, the U.S. Naval Medical Analysis Command, and others.
FinSMEs
09/07/2025
